Changes

Jump to navigation Jump to search

National Institutes of Health

16 bytes added, 12:26, 1 December 2021
m
wikify AIDS
{{Citation
|Title=When inquired about their involvement, an intactivist received this response
|Text=This is in response to your email dated June 30, 2010, to Dr. Francis S. Collins, {{MD}}, {{PhD}}, Director of the National Institutes of Health (NIH), concerning clinical trial #NCT01115335l, “Feasibility, Acceptability, and Safety of Neonatal Male Circumcision in Lusaka, Zambia,” and the premise upon which it was designed. That is, that circumcision prevents the transmission of [[HIV]] infection. Your email has been forwarded to the National Institute of Allergy and Infectious Diseases (NIAID), the NIH component with primary responsibility for research on [[HIV]]/[[AIDS]].
The World Health Organization/Joint United Nations Program on [[HIV]]/[[AIDS ]] has concluded that the research evidence that male circumcision is efficacious in reducing sexual transmission of [[HIV]] from women to men is compelling, and that it has been proven beyond reasonable doubt. (http://data.unaids.org/pub/Report/2007/mc_recommendations_en.pdf) Their report and additional information is available on male circumcision for [[HIV]] prevention at www.malecircumcision.org. This Web site/clearinghouse is a service of the World Health Organization (WHO), the Joint United Nations Programme on [[HIV]]/[[AIDS ]] (UNAIDS), the AIDS Vaccine Advocacy Coalition (AVAC), and Family Health International (FHI).
You may also be interested to know that NIAID-supported research has found that medical circumcision can help heterosexual men significantly reduce their risk of acquiring two other sexually transmitted infections—[[herpes]] simplex virus type 2 (HSV2), the cause of genital [[herpes]], and human papillomavirus (HPV), which can cause penile and cervical cancer and genital warts. (see http://www.niaid.nih.gov/about/whoWeAre/Documents/scienceadvances2009.pdf).
[...]
No matter how effective a preventive [[HIV]] vaccine is, however, we will need to evaluate and administer it in combination with other biomedical and behavioral [[HIV]] prevention tools. No single [[HIV]] prevention strategy will control and ultimately end the [[HIV]]/[[AIDS ]] pandemic. That is why it is important for NIAID to continue supporting promising research on vaginal and rectal microbicides, pre-exposure prophylaxis (PrEP) and expanded [[HIV]] testing with linkage to care. That is also why public health workers will continue to advocate and implement scientifically proven [[HIV]] prevention strategies such as condom use, medically supervised adult <strong>male circumcision</strong>, harm-reduction strategies for injection drug users and the prevention of mother-to-child transmission of [[HIV]].
|Author=
|Source=
administrator, administrators, Bureaucrats, Interface administrators, Administrators
22,335
edits

Navigation menu